Lipidor presents Nomination Committee
STOCKHOLM, 9th December 2021 – In accordance with the current nomination committee instructions for Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI), as resolved by the AGM 2020, Lipidor shall have a nomination committee consisting of four members.
The three largest shareholders who are registered with Euroclear Sweden AB on the last day of September before the meeting are to be contacted by the company's Chairman of the Board. The three largest shareholders each have the right to appoint a member of the Nomination Committee. In addition, the Chairman of the Board shall be a member of the Nomination Committee.
As of September 30, 2021, the three largest shareholders were Cerbios-Pharma SA, Råsunda Förvaltning AB and Aurena Laboratories AB. All have agreed to be part of the Nomination Committee.
The Nomination Committee consists of the following members:
- Anton van Troostenburg, appointed by Cerbios-Pharma SA
- Per Nilsson, appointed by Råsunda Förvaltning AB
- Magnus Hedman, appointed by Aurena Laboratories AB
- Fredrik Sjövall, Chairman of the Board, convener
No later than six weeks before the Annual General Meeting, the Nomination Committee shall submit proposals regarding: Chairman of the Meeting; Chairman, other Board members and any Deputy Board members; fees to the Chairman and other Board members; election of auditor and fee to auditor; and, where applicable, amendments to these instructions.
The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting 2022 and on the company's website, www.lipidor.se.
Shareholders who wish to submit proposals to Lipidor's Nomination Committee prior to the 2022 Annual General Meeting can do so via e-mail to: info@lipidor.se (with subject ”Nomination Committee”) or by post to the address: Lipidor AB, FAO: Nomination Committee, Svärdvägen 13, SE-182 33 Danderyd.
Lipidor's Annual General Meeting 2022 will be held on Thursday 2nd June 2022 at 10.00am in Danderyd. A request to have a matter considered at the meeting must have been received no later than the 14th April 2022 in order to be included in the notice.
Information
The information was provided for publication through the office of the below contact person on 9th December 2021 at 8.00am (CET).
For further information, please contact:
Fredrik Sjövall, Chairman of the Board
Telephone: +46 (0)70 645 08 75
Email: fredrik.sjovall@lipidor.se
Certified Adviser
Erik Penser Bank AB
Telephone: +46 (0)8 463 80 00
Email: certifiedadviser@penser.se
About AKVANO®
AKVANO® is an innovative water-free and sprayable technology for the formulation of drugs and is particularly suitable for local application to, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, constitute carriers of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates, and a thin lipid layer is formed on the skin surface for effective release of the active substance.
About Lipidor AB
Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor’s shares are listed on the Nasdaq First North Growth Market (LIPI).
Tags: